Neuland Laboratories Limited
NEULANDLAB
Quarterly Score
Showing the latest 12 quarterly points (newest to oldest).
Score context (latest 12 quarters)
No additional context available.
No additional context available.
No additional context available.
No additional context available.
No additional context available.
No additional context available.
No additional context available.
No additional context available.
No additional context available.
Management maintained guidance for 'strong growth' in FY26 over the FY24 base, citing visibility from the commercialization of one new CMS molecule this year and the ramp-up of the Unit 3 production block in H2 FY26.
Quarter summary
- The quarter was characterized by 'subdued' performance in Specialty GDS and uneven order flow in the CMS segment, which management attributed to the inherent volatility of the CDMO business model.
- Strategic focus is shifting toward large-scale peptide manufacturing, with a new facility under construction and validation of a new production block at Unit 3 completed.
Rationale
- Material deterioration in top-line and bottom-line performance: Total income declined 32.4% YoY to ₹300.6 crores, leading to a massive PAT drop from ₹98.3 crores to ₹13.7 crores.
- Significant margin compression due to operating deleverage: EBITDA margins collapsed to 14.4% (from significantly higher levels in FY25) as fixed costs were not covered by the suppressed revenue base.
Management reaffirmed that FY26 will be a year of strong growth. They expect the commercialization of one additional molecule within the current financial year and anticipate momentum in the top two commercial CMS molecules to sustain through H2.
Quarter summary
- Strategic pivot toward the Peptide CDMO space is accelerating, with a four-module large-scale facility under construction and Module-1 expected to be operational next fiscal year.
- Operationalization of a new block in Unit-III for a high-demand commercial molecule has been completed, with commercial shipments expected to scale following Q2 validation.
Rationale
- Exceptional revenue growth of 63.7% YoY to ₹516 Cr in Q2FY26, driven by top-two commercial CMS (CDMO) molecules performing strongly.
- Significant margin expansion with EBITDA at 30.4% and Gross Margins rising to 60.1% (up from 56.3% YoY), reflecting a structural shift toward higher-value CMS business which now exceeds 50% of revenue.
Management is 'guarded' and optimistic about growth for FY26 but declined to provide specific numerical guidance. They noted that Unit 3 capacity ramp-up is ongoing and new business deliveries are expected over a 12-24 month horizon.
Quarter summary
- Structural transition to a CDMO-heavy model continues, with commercial CMS projects now contributing over 50% of total revenue.
- Strategic pivot towards complex modalities is underway with the commissioning of a new peptide facility expected in July and the approval of a state-of-the-art R&D campus in Genome Valley.
Rationale
- Revenue growth of 11.4% YoY (₹447.8 Cr) is stable but margins faced compression; EBITDA margin dropped to 19% (21% adjusted for labor code impact) due to a product mix shift and the absence of high-margin CMS shipments during the quarter.
- Working capital efficiency has deteriorated to 145 days (vs 94 days in FY25), with inventory holding at 124 days, resulting in negative Free Cash Flow of ₹9.2 Cr for 9MFY26 despite significant customer advances.
Future Growth Prospects
Catalysts (next 12-24 months)
Swipe or use arrows to browse all triggers.
Unit 3 Production Ramp-up
Timeline
- commissionedQ1FY26 · concall
Unit 3 production block has been capitalized, and we expect commercial production to start later in this fiscal year.
- commissionedQ2FY26 · concall
Capacity for Ezetimibe enhanced from 8 MTPA to 12 MTPA... Unit 3 block is commissioned.
Capacity for key Prime GDS product specifically enhanced.
Show full timeline (3)
- scaledQ3FY26 · concall
Ramp-up has started and it actually we've seen volumes being shipped in Q3... going to take maybe another one or two quarters to really pick up.
Shift from commissioning to active volume shipping.
Supporting evidence
• Q3FY26 · concall · Expansion of capacity for the additional volume of the CMS product expansion has been successfully completed. That ramp-up has started.
Large-scale Peptide Module 1 Commissioning
Timeline
- in progressQ1FY26 · concall
Our peptide investment plan is on track... expect the new facility for peptides to be completed in the next financial year.
- in progressQ2FY26 · concall
Building a four-module large-scale peptide facility... Module-1 completely ready and operational by next financial year.
Specific module breakdown and SPPS reactor sizes (2,000-liter) disclosed.
Show full timeline (3)
- in progressQ3FY26 · concall
Ready for commissioning in July. Other than that, a lot of early-stage interest is there... Big pharma is engaging with us on peptides.
Firm July date set; early stage interest from 5-6 innovators confirmed.
Supporting evidence
• Q3FY26 · concall · Module-1, along with civil for Module-2, I think we are looking at ballpark Rs. 250 crores-Rs. 280 crores... ready for commissioning in July.
New CMS Molecule Commercialization
Timeline
- announcedQ2FY26 · concall
In line with our expectations, we should see the commercialization of another molecule this year.
- scaledQ3FY26 · concall
We did see the commercialization of a molecule, but we will see a lot more contribute over the next few quarters.
Shift from expectation to actual commercialization and tail-end shipping.
Supporting evidence
• Q3FY26 · concall · Additional CMS molecule... shipments that I believe went out in the tail end of the quarter... believe it will be a continuous business going forward.
Variant perception
Non-consensus viewMarket may underappreciate the significant scale shift from pilot to 6.37 KL peptide synthesizer capacity, a configuration unmatched by most Indian CDMOs.
- Large-scale peptide manufacturing capabilities provide a 'white space' entry into new Big Pharma relationships.
Show more (1)Hide extras
- New state-of-the-art R&D center in Genome Valley (140k sq ft) accelerates complex process design.
- High concentration in top 10 customers (76% company-wide) creates single-event logistical risks.
Quick takeaway
Consistent execution of 19 commercial CMS molecules and Unit 3 capacity ramp-up.
Risk watch: Inherent lumpiness of CMS shipments causing quarterly volatility.
Show details (2 drivers, 2 risks)Hide details
Drivers
- Consistent execution of 19 commercial CMS molecules and Unit 3 capacity ramp-up.
- GDS Prime portfolio led by Ezetimibe and Mirtazapine maintaining steady volumes.
Risks
- Inherent lumpiness of CMS shipments causing quarterly volatility.
- Delayed shipments of high-margin GDS products like Paliperidone due to customer operational issues.
Quick takeaway
Securing early commercial manufacturing arrangement for a peptide NCE from the 5-6 active projects.
Risk watch: Execution delays in the ₹250 Cr Module-1 peptide facility commissioning.
Show details (2 drivers, 2 risks)Hide details
Drivers
- Securing early commercial manufacturing arrangement for a peptide NCE from the 5-6 active projects.
- Operating leverage kicks in as revenue crosses ₹500 Cr quarterly threshold consistently.
Risks
- Execution delays in the ₹250 Cr Module-1 peptide facility commissioning.
- Raw material cost volatility for specialty intermediates.
Quick takeaway
Operational or logistical delays at customer ends for large individual CMS shipments.
Risk watch: Geopolitical risks impacting the 89% export revenue base.
Show details (2 drivers, 2 risks)Hide details
Drivers
- Operational or logistical delays at customer ends for large individual CMS shipments.
- Failure of late-stage clinical molecules in the CMS pipeline (98 projects active).
Risks
- Geopolitical risks impacting the 89% export revenue base.
- Increased overheads including impact from labor codes (₹10 Cr in Q3FY26).
Quick takeaway
Consistent execution of 19 commercial CMS molecules and Unit 3 capacity ramp-up.
Risk watch: Inherent lumpiness of CMS shipments causing quarterly volatility.
Show details (2 drivers, 2 risks)Hide details
Drivers
- Consistent execution of 19 commercial CMS molecules and Unit 3 capacity ramp-up.
- GDS Prime portfolio led by Ezetimibe and Mirtazapine maintaining steady volumes.
Risks
- Inherent lumpiness of CMS shipments causing quarterly volatility.
- Delayed shipments of high-margin GDS products like Paliperidone due to customer operational issues.
Quick takeaway
Securing early commercial manufacturing arrangement for a peptide NCE from the 5-6 active projects.
Risk watch: Execution delays in the ₹250 Cr Module-1 peptide facility commissioning.
Show details (2 drivers, 2 risks)Hide details
Drivers
- Securing early commercial manufacturing arrangement for a peptide NCE from the 5-6 active projects.
- Operating leverage kicks in as revenue crosses ₹500 Cr quarterly threshold consistently.
Risks
- Execution delays in the ₹250 Cr Module-1 peptide facility commissioning.
- Raw material cost volatility for specialty intermediates.
Quick takeaway
Operational or logistical delays at customer ends for large individual CMS shipments.
Risk watch: Geopolitical risks impacting the 89% export revenue base.
Show details (2 drivers, 2 risks)Hide details
Drivers
- Operational or logistical delays at customer ends for large individual CMS shipments.
- Failure of late-stage clinical molecules in the CMS pipeline (98 projects active).
Risks
- Geopolitical risks impacting the 89% export revenue base.
- Increased overheads including impact from labor codes (₹10 Cr in Q3FY26).
Story of the Stock - Top Strategies
Peptide Business Expansion
Significant investment in peptide facility to capture growing market demand.
Show more
Neuland is investing significantly in a large-scale peptide facility to capitalize on the growing peptide API market, aiming to attract major commercial opportunities.
Evidence
CMS Growth and Diversification
Continued strong growth in CMS business driven by new projects and innovator collaborations.
Show more
The CMS business is a key growth driver, with a strong pipeline of projects and increasing interest from innovators, leading to a steady influx of new business.
Evidence
Operational Excellence and Capacity Expansion
Investment in Unit 3 capacity and focus on operational excellence to drive future growth.
Show more
Neuland has capitalized Unit 3 and expects commercial production to start, contributing to business momentum. Investments in capacity are ahead of demand.
Evidence
Business Segments
Community
Share your view anonymously. Comments are public and sorted newest first.
Anonymous post · 1500 characters left